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Results: Using the digital log, the data concerning the TLP 
can be stored in a structured way, rather than in open text 
parts of a patient’s dossier. The action codes regarding the 
anatomical changes that are present in the log showed a 
clear overview of possible variations during treatment. The 
RTTs scored an average of 7.8/10 in the questionnaire on the 
digital log overview. In succession, this overview showed a 
clear course of action regarding these anatomical changes 
using the TLP. 
 
Conclusion: The implementation and use of a digital log 
improves the overview of the anatomical changes observed 
on CBCT during radiotherapy. Moreover, the data gathered 
within the log can retrospectively be used for clinical or 
research questions regarding clinical IGRT decisions for a 
specific target area. 
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Purpose or Objective: Vestibular schwannomas (acoustic 
neuromas) are common benign tumors that arise from the 
Schwann cells of the vestibular nerve. Management options 
include observation with neuroradiological follow-up, 
microsurgical resection or stereotactic radiotherapy (SRS). 
The aim of the study was to evaluate tumor size and 
treatment tolerance of patients treated with CyberKnife (CK) 
radiosurgery for vestibular schwannoma (VS). 
 
Material and Methods: Between 2011 and 2014, 96 patients 
with 100 vestibular schwannomas were treated with SRS using 
CK. The vestibular schwannomas of 5 patients were 
associated with type II neurofibromatosis. Twenty patients 
were operated on before radiosurgery. All patients had more 
than one year follow-up. The median age at the time of 
treatment was 59 ( range 21-88 years). Median tumor 
diameter was 18 mm (range 3-48 mm) and the median 
prescribed dose was 16 Gy (12-21 Gy). In 29 patients, single 
dose of 12-18 Gy was delivered, in 31 total dose of 12-16 Gy 
was delivered with two fractions and the remaining 40 
patients were treated with 15-21 Gy delivered in 3 fractions 
baseline. Hearing was classified according to the Gardner 
Robertson grading scale (48% of patients had serviceable 
hearing).  
 
Results: At 12 month after SRS we observed that :15% of 
tumors slightly expanded, in 8% patients slight expansion of 
tumor followed by regression, 11% of tumors increased in 
size, but then remained stable, 58% were stable in size and 
8% responded to therapy. Overall, tumor swelling was, thus, 
observed in 34% of patients. At first year no patient required 
neurosurgical intervention due to tumor progression or 
brainstem compression symptoms. 77% patients had stable 
level of hearing after SRS, 9% declared improvement and 14% 
worsening of hearing. The rate of complications was very 
low, with most consisting of a transient worsening of 
preexisting symptoms. At the last assessment, full facial and 
trigeminal nerve function was preserved in 95% and 98% of 
patients, respectively; the only facial deficit (House-
Brackmann grade III) occurred in patient who received a 
single dose of 18 Gy in one fraction early in our experience, 
the remaining were mild, grade II dysfunctions. None of the 
patients treated with doses lower than 13 Gy experienced 
facial or trigeminal neuropathy. 
 
Conclusion: Cyber Knife radiosurgery is a safe and effective 
treatment for VS characterized by high probability of 
retaining functional hearing and facial and trigeminal nerve 
function preservation. In about one third of patients a tumor 
swelling after treatment is observed but reliable tumor 
control and persistence of neural dysfunctions assessment 
requires longer follow-up. 
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Purpose or Objective: Soft tissue sarcomas are rare 
malignancies, commonly arising in limbs, with an annual 
incidence of 3,298 cases in the UK in 2010. Their rarity leads 
to a lack of published data and experience in limb 
immobilisation for radiotherapy planning. The IMRiS trial is a 
phase II study of intensity modulated radiotherapy (IMRT) in 
primary bone and soft tissue sarcoma, due to open in late 
2015. As part of a pre-trial quality assurance (PT QA) 
programme, we report on the current UK practice of limb 
soft tissue sarcoma (LSTS) immobilization and the 
significance for multi-centre trial recruitment. 
 
Material and Methods: A facility questionnaire (FQ) was 
circulated to 29 IMRiS centres to investigate variation in 
immobilisation devices (ID), planning techniques, and imaging 
protocols. A workshop was held to address limb sarcoma 
immobilisation and patient set up. Robustness of patient 
setup at each centre was evaluated based on setup audits, 
frequency of imaging and the number of patients (pts) 
treated per centre per annum. 
 
Results: 27 questionnaires were returned. Less than 1/3 of 
the responders routinely treat their pts with IMRT (8/27). The 
remaining 2/3 have little or no experience with IMRT for 
LSTS. Vacuum bags are currently the most popular ID (9/27), 
followed by thermoplastic shells (7/27), limb boards (5/27), 
other devices (3/27) of which 2 used in-house developed and 
customisable devices, and 1 used common positioning pads. 2 
centres combined the use of vacuum bag and shell. 9 centres 
had audited their setup. However, only 4 had calculated their 
setup margins on the basis of systematic and random error. 
The majority of centres follow the recommendations to 
perform imaging on days 1 to 5 and then weekly. 6 centres 
perform daily imaging (all 6 treat LSTS with IMRT). Of 6 
centres with a high level of setup robustness, 3 are IMRT 
centres. On average centres treat 24 pts annually (range 3-
53). Currently over half the centres treat less than the 
calculated average number of pts. 
 
Conclusion: The results from the FQ and workshop 
demonstrate variations in treatment modality, ID and imaging 
frequency across the UK. 70% of IMRiS participating centres 
will be implementing or further developing IMRT in order to 
treat LSTS in the study. This will require a change in 
treatment modality (from 3DCRT to IMRT) in 9 centres. 
Comprehensive PT QA is required to ensure quality in a trial 
to be run at centres with such different levels of experience. 
